America's Future · 80th Anniversary

Trial Engine

Match a patient's basic profile to the research trials they likely qualify for — and see exactly why. Privacy-first, illustrative, and not medical advice.

Patient profile

Nothing here is saved or sent. Matching runs on your device.

Likely matches

1 qualifying

  • Early-Detection Screening Cohort

    National Oncology Alliance · Observational · Seattle, WA

    Likely qualifies
    Criteria met100%

    Blood-based early-detection screening in higher-risk adults to validate a multi-cancer signal at early stage.

    Why it qualifies

    • Studies Cancer, which matches the profile.
    • Age 58 is within the 45–70 window.
    • Targets early-stage disease, matching the profile.
    • Open to all.
    • Treatment-naive required — profile reports none.
    See full eligibility breakdown →

  • Prevention Lifestyle Cohort

    Heartland Public Health Trust · Phase II · Des Moines, IA

    Not a match
    Criteria met73%

    Structured diet-and-activity program for adults at early metabolic risk, measuring progression to insulin dependence.

    Why it qualifies

    • Age 58 is within the 30–65 window.
    • Targets early-stage disease, matching the profile.
    • Open to all.
    • Treatment-naive required — profile reports none.

    What rules it out

    • Studies Diabetes; profile lists Cancer.
    See full eligibility breakdown →

  • Early Rhythm Monitoring Study

    Atlantic Cardiology Consortium · Phase II · Cleveland, OH

    Not a match
    Criteria met69%

    Wearable rhythm monitoring to catch early-stage heart disease before symptoms emerge in midlife adults.

    Why it qualifies

    • Age 58 is within the 45–70 window.
    • Targets early-stage disease, matching the profile.
    • Open to all.

    What rules it out

    • Studies Heart disease; profile lists Cancer.
    See full eligibility breakdown →

  • GLP-1 Outcomes Study

    Meridian Endocrine Network · Phase III · Austin, TX

    Not a match
    Criteria met69%

    Long-term cardiovascular outcomes of a once-weekly GLP-1 therapy in adults managing early-stage type 2 diabetes.

    Why it qualifies

    • Age 58 is within the 40–75 window.
    • Targets early-stage disease, matching the profile.
    • Open to all.

    What rules it out

    • Studies Diabetes; profile lists Cancer.
    See full eligibility breakdown →

  • Women's Cardio-Metabolic Study

    Cascade Women's Health Institute · Phase II · Portland, OR

    Not a match
    Criteria met69%

    Sex-specific metabolic therapy evaluated in early-stage diabetes among post-menopausal women.

    Why it qualifies

    • Age 58 is within the 55–80 window.
    • Targets early-stage disease, matching the profile.
    • Enrolls female participants, matching the profile.

    What rules it out

    • Studies Diabetes; profile lists Cancer.
    See full eligibility breakdown →

  • Immunotherapy Basket Trial

    National Oncology Alliance · Phase I/II · Houston, TX

    Not a match
    Criteria met63%

    Biomarker-selected immunotherapy for adults with advanced solid tumors, open across multiple tumor types.

    Why it qualifies

    • Studies Cancer, which matches the profile.
    • Age 58 is within the 18–75 window.
    • Open to all.

    What rules it out

    • Targets advanced stage; profile is early.
    • Requires a positive biomarker; profile is negative/unknown.
    See full eligibility breakdown →

  • Cardiac Recovery Trial

    Atlantic Cardiology Consortium · Phase III · Boston, MA

    Not a match
    Criteria met46%

    Supervised rehabilitation protocol for adults recovering from advanced heart disease following a cardiac event.

    Why it qualifies

    • Age 58 is within the 50–80 window.
    • Open to all.

    What rules it out

    • Studies Heart disease; profile lists Cancer.
    • Targets advanced stage; profile is early.
    See full eligibility breakdown →

Matching log

match.log
$ trial-engine match --local
registry: 7 trials  fnv1a:8f0f6c01
query fnv1a:e6aba37a
eligible: 1 / 7
  PASS  100%  Early-Detection Screening Cohort
  ----   73%  Prevention Lifestyle Cohort
  ----   69%  Early Rhythm Monitoring Study
  ----   69%  GLP-1 Outcomes Study
  ----   69%  Women's Cardio-Metabolic Study
  ----   63%  Immunotherapy Basket Trial
status: ok  (no data stored)

The log shows a deterministic fingerprint of the registry and your query (FNV-1a, not a cryptographic hash). It is proof the same inputs always produce the same run — no profile data leaves your device.